SLC5A2 and COVID-19: Up to date, the potential impact of glucose-lowering agents, especially the SGLT2 inhibitors, to potentially modify the symptoms of LCS remain unclear, whereby the current scientific research so far revealed controversial results in acute COVID-19 [67].